Beta Bionics BBNX
- Market cap
- $864.4M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 6.8×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $127.3M
- +44% on a year ago
- Net margin
- −65.3%
- Free cash flow yield
- −7.6%
Beta Bionics trades at 6.8× sales. Its trailing earnings are negative, so it has no PE. Revenue was $127.3M over the last twelve months, up 44% on a year earlier with a −65% net margin.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $12.9M | $15M | $16.7M | $20.4M | $17.6M+36% | $23.2M+54% | $27.3M+63% | $32.1M+57% | $27.6M+57% | $32M+38% | $35.5M+30% | |
| Cost of revenue | $5.7M | $7M | $7.8M | $8.8M | $8.7M+51% | $10.7M+54% | $12.1M+56% | $13.2M+51% | $11.2M+29% | $13.1M+22% | $15.2M+25% |
| Gross profit | $7.2M | $8.1M | $8.9M | $11.7M | $9M+25% | $12.5M+55% | $15.1M+70% | $18.9M+62% | $16.4M+83% | $18.9M+51% | $20.3M+35% |
| R&D | $5.5M | $6.3M | $5.1M | $9.2M | $7.6M+39% | $8.9M+40% | $8.2M+59% | $10.1M+10% | $10.4M+36% | $10.2M+15% | $12M+46% |
| SG&A | $11.2M | $13.5M | $14.8M | $15.5M | $20M+79% | $23.5M+74% | $24M+63% | $24.9M+61% | $30.4M+52% | $34.2M+46% | $35M+46% |
| −$9.5M | −$11.8M | −$11M | −$13M | −$18.6M+97% | −$19.9M+69% | −$17M+55% | −$16.1M+24% | −$24.3M+30% | −$25.6M+29% | −$26.6M+56% | |
| Net income | −$12.4M | −$14.5M | −$9.7M | −$18.1M | −$28.7M+130% | −$16.9M+17% | −$14.2M+46% | −$13.5M−26% | −$21.9M−24% | −$23.4M+39% | −$24.4M+71% |
| −$2.07 | −$2.37 | −$1.46 | −$2.72 | −$0.93−55% | −$0.39−84% | −$0.33−77% | −$0.30−89% | −$0.49−47% | −$0.53+36% | −$0.52+58% | |
| 6M | 6.1M | 6.7M | 6.7M | 30.7M+410% | 43.4M+611% | 43.6M+555% | 44.2M+563% | 44.4M+45% | 44.5M+3% | 46.5M+7% |
EPS, diluted: Q4 FY24 and Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY24 and Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Beta Bionics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BBNXBeta Bionics | $864.4M | n/m | n/a | 6.8× | +44% | −65.3% | |
| IRMDIradimed | $1B | 42.5× | 41.5× | 11.4× | +11% | 26.8% | |
| MOVMovado | $710.9M | 17.7× | 13.4× | 1.0× | +5% | 6.0% | |
| IARTIntegra Lifesciences | $1.1B | 80.1× | 46.3× | 0.6× | +1% | 0.8% | |
| BVSBioventus | $1.1B | 17.1× | 27.1× | 1.9× | +4% | 9.4% | |
| STAAStaar Surgical | $1.3B | 356× | 144× | 3.7× | +51% | 1.1% | |
| CDRECadre | $1.3B | 38.9× | 35.9× | 2.0× | +20% | 5.3% | |
| EYENational Vision | $1.4B | 28.1× | 52.7× | 0.7× | +8% | 2.5% | |
| TCMDTactile Systems Technology | $518.1M | 21.2× | 62.3× | 1.5× | +17% | 7.1% | |
| LMATLemaitre Vascular | $1.9B | 28.5× | 42.0× | 7.1× | +12% | 25.0% | |
| INSPInspire Medical Systems | $1.9B | 14.5× | 56.6× | 2.2× | −0% | 15.0% | |
| Peer median | $1.2B | 28.3× | 44.1× | 1.9× | +9% | 6.5% |
More on Beta Bionics
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .